Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Maruti presents strong results
Tue, 27 Apr 11:30 am

The Indian markets continued to remain volatile during the previous two hours as profit booking continued in index heavyweights. While some buying interest was seen in stocks in the FMCG and power space; stocks from the realty, auto and banking sectors are out of favour.

BSE-Sensex is trading lower by 11 points while NSE-Nifty is trading 3 points below the dotted line. However, BSE-Midcap Index is up by 0.2% while the BSE-Smallcap index is trading 0.4% above yesterday's closing. The rupee is trading at 44.41 to the US dollar.

Maruti Suzuki released its 4QFY10 results yesterday. The company's topline during the quarter grew by 31% YoY on the back of a 22% YoY increase in volumes. Operating profits jumped by 147% during the quarter as operating margins expanded by 6.2% on the back of lower costs as a percentage of sales. Net profit grew by 170% YoY during the quarter. The performance of the quarter was aided by a lot of tailwinds like low interest rate environment, low base effect, government incentives and buoyant economic environment. However, we believe that FY10 was an aberration and going forward, the growth should be as its long term average.

As per a leading daily, Dr Reddy's Laboratories (DRL) has launched the generic version of hypertension drug Lotrel in the US market. The drug will be launched in capsules of 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg strengths. DRL will be facing competition from Teva, Lupin, Sandoz and Novartis who are already marketing the drug in the US. While DRL's officials have declined to divulge the target sales of this drug, the market is believed to be worth US$ 527 m. While the market is large, DRL will have to face stiff competition, more so as Mylan and Colbalt are also looking to enter this market.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Maruti presents strong results". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 23, 2018 (Close)